Biosimilar Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Product (Infliximab, Trastuzumab, Rituximab, Adalimumab, Bevacizumab, Cetuximab, Ranibizumab, Denosumab, Eculizumab, Other Pipeline Products), By Indication, By Region, And Segment Forecasts, 2025-2034

Report Id: 1218 Pages: 180 Last Updated: 18 June 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Biosimilar Monoclonal Antibodies Market

Global Biosimilar Monoclonal Antibodies Market, by Product, 

Global Biosimilar Monoclonal Antibodies Market, by Indication, Autoimmune Diseases

  • Oncology
  • Ophthalmic Disorders
  • Bone Disorders
  • Rare Hematologic/Neurologic Disorders
  • Hematologic Support
  • Inflammatory Bowel Disease
  • Other Indication

Global Biosimilar Monoclonal Antibodies Market, by Region,

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Biosimilar Monoclonal Antibodies Market, by Country, 

  • U.S.
  • Canada

Europe Biosimilar Monoclonal Antibodies Market, by Country, 

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Biosimilar Monoclonal Antibodies Market, by Country, 

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 

  • GCC Countries
  • South Africa
  • Rest of the Middle East & Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Biosimilar Monoclonal Antibodies Market Snapshot

Chapter 4. Global Biosimilar Monoclonal Antibodies Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Clinical Trial/Pipeline Analysis

4.9. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 2: By Products Estimates & Trend Analysis

5.1. By Products & Market Share, 2024 & 2034

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:

5.2.1. Infliximab

5.2.2. Trastuzumab

5.2.3. Rituximab

5.2.4. Adalimumab

5.2.5. Bevacizumab

5.2.6. Ranibizumab

5.2.7. Denosumab

5.2.8. Eculizumab

5.2.9. Filgrastim

5.2.10. Pegfilgrastim

5.2.11. Ustekinumab

5.2.12. Other Pipeline drugs

Chapter 6. Market Segmentation 4: By Indications Estimates & Trend Analysis

6.1. By Indications & Market Share, 2024 & 2034

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indications:

6.2.1. Autoimmune Diseases

6.2.2. Oncology

6.2.3. Ophthalmic Disorders

6.2.4. Bone Disorders

6.2.5. Rare Hematologic/Neurologic Disorders

6.2.6. Hematologic Support

6.2.7. Inflammatory Bowel Disease

6.2.8. Other Indication

Chapter 7. Biosimilar Monoclonal Antibodies Market Segmentation 5: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts By Products, 2021-2034

7.1.2. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts By Types, 2021-2034

7.1.3. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034

7.1.4. North America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by country, 2021-2034

7.2. Europe

7.2.1. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2021-2034

7.2.2. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2021-2034

7.2.3. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034

7.2.4. Europe Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2021-2034

7.3. Asia Pacific

7.3.1. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2021-2034

7.3.2. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2021-2034

7.3.3. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034

7.3.4. Asia Pacific Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2021-2034

7.4. Latin America

7.4.1. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2021-2034

7.4.2. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2021-2034

7.4.3. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034

7.4.4. Latin America Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2021-2034 

7.5. Middle East & Africa

7.5.1. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Products, 2021-2034

7.5.2. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) By Types, 2021-2034

7.5.3. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034

7.5.4. Middle East & Africa Biosimilar Monoclonal Antibodies Market revenue (US$ Million) by country, 2021-2034

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles 

8.2.1. Accord BioPharma Inc.

8.2.2. Alvotech USA Inc.

8.2.3. Amgen Inc.

8.2.4. Amneal Pharmaceuticals LLC

8.2.5. Biocon Biologics Inc.

8.2.6. Biogen Netherlands B.V.

8.2.7. Biosimilar Collaborations Ireland Limited

8.2.8. Bio-Thera Solutions, Ltd.

8.2.9. Boehringer Ingelheim Pharmaceuticals, Inc.

8.2.10. Celltrion Healthcare Hungary Kft.

8.2.11. Coherus BioSciences, Inc.

8.2.12. CuraTeQ Biologics s.r.o

8.2.13. Eli Lilly and Company

8.2.14. FGK Representative Service GmbH

8.2.15. Formycon AG

8.2.16. Fresenius Kabi

8.2.17. Gedeon Richter Plc.

8.2.18. Hexal AG

8.2.19. Hong Kong King-Friend Industrial Company Limited

8.2.20. Hospira Inc., a Pfizer Company

8.2.21. Juta Pharma GmbH

8.2.22. Kashiv BioSciences, LLC

8.2.23. Mabxience Research SL

8.2.24. Medice Arzneimittel Pütter GmbH Co. KG

8.2.25. Midas Pharma GmbH

8.2.26. Mundipharma Corporation (Ireland) Limited

8.2.27. Pfizer Inc.

8.2.28. Qilu Pharma Spain S.L.

8.2.29. Ratiopharm GmbH

8.2.30. Reddy Holding GmbH

8.2.31. Samsung Bioepis Co., Ltd.

8.2.32. Sandoz Inc.

8.2.33. Sanofi

8.2.34. Stada Arzneimittel AG

8.2.35. Strides Pharma (Cyprus) Limited

8.2.36. Tanvex BioPharma USA, Inc.

8.2.37. Techdow Pharma Netherlands B.V.

8.2.38. Teva GmbH

8.2.39. Theramex Ireland Limited

8.2.40. Other prominent players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
1081
Security Code field cannot be blank!

Frequently Asked Questions

Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics, Intas Pharmaceuticals Limited

Biosimilar Monoclonal Antibodies Market Size is valued at USD 7.8 Bn in 2024 and is predicted to reach USD 32.1 Bn by the year 2034

Biosimilar Monoclonal Antibodies Market is expected to grow at a 15.3% CAGR during the forecast period for 2025-2034.

Products and Indication are the key segments of the Biosimilar Monoclonal Antibodies Market.

North America region is leading the Biosimilar Monoclonal Antibodies Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying